Keyphrases
Tumor
70%
Overall Survival
61%
Chemotherapy
51%
Phase II Study
50%
Non-small Cell Lung Cancer (NSCLC)
49%
Breast Cancer
43%
Progression-free Survival
42%
Phase II Trial
41%
Confidence Interval
40%
Relapsed or Refractory
32%
Clinical Trials
29%
Rituximab
27%
Lung Cancer
24%
Metastatic Breast Cancer
23%
Targeted Therapy
22%
Hazard Ratio
21%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
21%
Mantle Cell Lymphoma
21%
Doxorubicin
20%
Follicular Lymphoma
20%
Radiation Therapy
19%
In Cancer
18%
Diffuse Large B-cell Lymphoma (DLBCL)
18%
Adverse Events
18%
Brentuximab Vedotin
18%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
17%
Cisplatin
17%
Gemcitabine
17%
Complete Response
16%
Triple-negative Breast Cancer
16%
NCCN Guidelines
16%
Partial Response
16%
Programmed Death-ligand 1 (PD-L1)
15%
Docetaxel
15%
Colorectal Cancer
15%
Clinical Outcomes
15%
Oncology
15%
Pancreatic Cancer
15%
Overall Response Rate
15%
Hodgkin Lymphoma
14%
Lymphoma
14%
Carboplatin
14%
Pembrolizumab
14%
Median Overall Survival
14%
Circulating Tumor DNA (ctDNA)
14%
T Cells
13%
Median Progression-free Survival
13%
Non-Hodgkin Lymphoma
13%
Solid Tumors
13%
Older Adults
13%
Head-and-neck Squamous Cell Carcinoma (HNSCC)
13%
Immune Checkpoint Inhibitors
13%
Phase I Study
13%
Paclitaxel
13%
Bevacizumab
12%
Pancreatic Ductal Adenocarcinoma
12%
Cyclophosphamide
12%
Placebo
12%
Randomized Phase II Trial
12%
Objective Response Rate
12%
Melanoma
12%
Previously Treated
12%
High Risk
12%
Disease Progression
12%
Glioblastoma
11%
Monotherapy
11%
Response Rate
11%
Small Cell Lung Cancer
11%
Stable Disease
11%
Sarcoma
11%
Metastasis
11%
Tumor Cells
11%
Peripheral T-cell Lymphoma
11%
Whole Genome
11%
Human Epidermal Growth Factor Receptor 2 (HER2)
10%
Maximum Tolerated Dose
10%
Treatment Options
10%
Chronic Lymphocytic Leukemia
10%
Neutropenia
10%
Systemic Therapy
10%
Antitumor Activity
10%
Tumor Microenvironment
10%
Cetuximab
10%
Dose Escalation
10%
Older Patients
10%
Newly Diagnosed
10%
Prednisone
10%
Pan-cancer Analysis
10%
Multiple Myeloma
10%
Soft Tissue Sarcoma
10%
Malignancy
10%
Neoadjuvant
9%
Head-and-neck Cancer
9%
Radiotherapy
9%
United States
9%
Resection
9%
Etoposide
9%
Cancer Types
9%
Colorectal Liver Metastases
9%
Cancer Treatment
9%
Medicine and Dentistry
Neoplasm
100%
Diseases
69%
Malignant Neoplasm
66%
Breast Cancer
63%
Overall Survival
62%
Non Small Cell Lung Cancer
43%
Progression Free Survival
41%
Clinical Trial
34%
Oncology
29%
Cancer
29%
Radiation Therapy
28%
Lung Cancer
28%
Immunotherapy
26%
Metastatic Carcinoma
25%
Rituximab
24%
Targeted Therapy
20%
Arm
20%
Adverse Event
20%
Recurrent Disease
20%
Hodgkin's Lymphoma
18%
Mantle Cell Lymphoma
18%
Biological Marker
18%
Non-Hodgkin Lymphoma
17%
Diffuse Large B-Cell Lymphoma
17%
T Cell
16%
Hazard Ratio
16%
Melanoma
16%
Metastatic Breast Cancer
15%
Connective Tissue Cancer
14%
Cisplatin
14%
Doxorubicin
13%
Follicular Lymphoma
13%
Phase II Trials
13%
Triple Negative Breast Cancer
12%
Pembrolizumab
12%
Prostate Cancer
12%
Paclitaxel
12%
Colorectal Carcinoma
12%
Pancreas Cancer
12%
Small Cell Lung Cancer
12%
Brentuximab Vedotin
11%
Solid Malignant Neoplasm
11%
Systemic Therapy
11%
Circulating Tumor DNA
11%
Gemcitabine
11%
Pancreas Adenocarcinoma
11%
Soft Tissue Sarcoma
10%
Cancer Cell
10%
Peripheral T-Cell Lymphoma
10%
Immune Checkpoint Inhibitor
10%
Positron Emission Tomography
10%
Chemoradiotherapy
10%
Tumor Progression
10%
Placebo
10%
Cancer Therapy
10%
Quality of Life
9%
Carcinogenesis
9%
Cyclophosphamide
9%
Hormone Therapy
9%
Head and Neck Squamous Cell Carcinoma
9%
Glioblastoma
9%
B-Cell Chronic Lymphocytic Leukemia
8%
Epidermal Growth Factor Receptor
8%
Carboplatin
8%
B Cell
8%
Multiple Myeloma
8%
Tumor Cell
8%
Human Immunodeficiency Virus
8%
Classical Hodgkin Lymphoma
8%
Neoadjuvant Chemotherapy
7%
Systematic Review
7%
Squamous Cell Carcinoma
7%
Colorectal Liver Metastasis
7%
Disease Free Survival
7%
Survival Rate
7%
Bevacizumab
7%
Nivolumab
7%
B-Cell Lymphoma
7%
Rectum Cancer
7%
Disease Exacerbation
7%
Primary Tumor
6%
Prognostic Factor
6%
Wart Virus
6%
Hematopoietic Cell
6%
Adjuvant Chemotherapy
6%
Malignant Peripheral Nerve Sheath Tumor
6%
Cetuximab
6%
Vincristine
6%
Head and Neck Cancer
6%
Bendamustine
6%
Health Care Cost
6%
Stem Cell Transplant
6%
Monotherapy
6%
Lenalidomide
6%
Neutropenia
6%
Etoposide
6%
Ibrutinib
6%
Cohort Analysis
6%
Prednisone
6%
Neurofibromatosis Type I
6%
Pharmacology, Toxicology and Pharmaceutical Science
Neoplasm
79%
Chemotherapy
66%
Diseases
59%
Malignant Neoplasm
59%
Overall Survival
56%
Progression Free Survival
47%
Non Small Cell Lung Cancer
47%
Breast Cancer
35%
Rituximab
30%
Adverse Event
29%
Clinical Trial
29%
Lung Cancer
26%
Paclitaxel
22%
Doxorubicin
21%
Phase II Trials
20%
Nonhodgkin Lymphoma
19%
Metastatic Breast Cancer
19%
Solid Malignant Neoplasm
18%
Follicular Lymphoma
16%
Biological Marker
16%
Prostate Cancer
16%
Immunotherapy
15%
Cisplatin
15%
Diffuse Large B Cell Lymphoma
15%
Docetaxel
15%
Mantle Cell Lymphoma
15%
Carboplatin
14%
Cyclophosphamide
14%
Small Cell Lung Cancer
14%
Gemcitabine
14%
Placebo
13%
Recurrent Disease
13%
Epidermal Growth Factor Receptor
12%
Hodgkin Disease
11%
Chemoradiation Therapy
11%
Pharmacokinetics
10%
Bevacizumab
10%
Monotherapy
10%
Colorectal Carcinoma
10%
Melanoma
10%
Neutropenia
10%
Glioblastoma
10%
Remission
9%
Brentuximab Vedotin
9%
Etoposide
9%
Pembrolizumab
9%
Bendamustine
9%
Cetuximab
9%
Head and Neck Squamous Cell Carcinoma
9%
Vincristine
9%
Carcinogenesis
9%
Maximum Tolerated Dose
9%
Pancreas Cancer
9%
Prednisone
8%
Antitumor Activity
8%
Triple Negative Breast Cancer
8%
Tumor Growth
8%
Soft Tissue Sarcoma
8%
Pancreas Adenocarcinoma
8%
Disease Exacerbation
8%
Phase III Trials
8%
Tolerability
8%
Chronic Lymphatic Leukemia
8%
Survival Rate
7%
Leukemia
7%
Immune Checkpoint Inhibitor
7%
Bortezomib
7%
Lenalidomide
7%
Diarrhea
7%
Pemetrexed
6%
Connective Tissue Cancer
6%
Receptor
6%
Thrombocytopenia
6%
Disease Free Survival
6%
Circulating Tumor DNA
6%
Palbociclib
6%
Peripheral T Cell Lymphoma
6%
Transitional Cell Carcinoma
6%
Erlotinib
5%
Endocrine Therapy
5%
Castration Resistant Prostate Cancer
5%
Anemia
5%
Squamous Cell Carcinoma
5%
Combination Therapy
5%
Estrogen Receptor
5%
Nivolumab
5%
Renal Cell Carcinoma
5%
Phosphatidylinositol 3 Kinase
5%
Irinotecan
5%
Cyclin Dependent Kinase 4
5%
Liver Cell Carcinoma
5%
Temozolomide
5%
Everolimus
5%
Methotrexate
5%
Head and Neck Cancer
5%
Phase I Trials
5%
Nausea
5%
Febrile Neutropenia
5%
Colon Carcinoma
5%
B Cell Lymphoma
5%